BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 22, 2011 - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, England.

The data related to BCX4208 will be presented during a poster session scheduled for Thursday, May 26, 2011 from 8:00-3:30 p.m. GMT. The two posters to be presented during the session include:

 

  • Presentation Number THR0027: “BCX4208, A Novel Urate-Lowering Therapy, was Generally Safe and Well-Tolerated in Two 3-Week Studies in Gout Subjects”
  • Presentation Number THU0011: “BCX4208 Shows Synergistic Reductions in Serum Uric Acid (sUA) in Gout Patients when Combined with Allopurinol”

Copies of the abstracts are available and can be viewed online through the EULAR website.

About BCX4208

BCX4208 is a next generation purine nucleoside phosphorylase (PNP) inhibitor with the potential for once-a-day oral dosing suitable for chronic administration. With its unique mechanism of action, clinical activity and safety in clinical studies to date, as well as its potential synergy with approved therapies, BCX4208 may address unmet medical needs across a broad spectrum of inflammatory and autoimmune diseases. In September 2010, BioCryst reported positive results from its Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout, announcing that the study met its primary endpoint related to serum uric acid (sUA) reduction, demonstrated a dose-response for both BCX4208 and allopurinol, and that the combination of BCX4208 and allopurinol was shown to be superior to either drug alone in sUA reduction.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

 

Contact: BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910 (investors)
or
WCG
Carolyn Wang, 415-946-1065 (media)

 

Posted: April 2011

View comments

Hide
(web4)